These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
537 related articles for article (PubMed ID: 16000591)
1. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591 [TBL] [Abstract][Full Text] [Related]
2. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767 [TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138 [TBL] [Abstract][Full Text] [Related]
4. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Yigitbasi OG; Younes MN; Doan D; Jasser SA; Schiff BA; Bucana CD; Bekele BN; Fidler IJ; Myers JN Cancer Res; 2004 Nov; 64(21):7977-84. PubMed ID: 15520205 [TBL] [Abstract][Full Text] [Related]
5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
6. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Park YW; Younes MN; Jasser SA; Yigitbasi OG; Zhou G; Bucana CD; Bekele BN; Myers JN Clin Cancer Res; 2005 Mar; 11(5):1963-73. PubMed ID: 15756022 [TBL] [Abstract][Full Text] [Related]
7. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626 [TBL] [Abstract][Full Text] [Related]
8. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290 [TBL] [Abstract][Full Text] [Related]
9. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601 [TBL] [Abstract][Full Text] [Related]
10. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Lu C; Kamat AA; Lin YG; Merritt WM; Landen CN; Kim TJ; Spannuth W; Arumugam T; Han LY; Jennings NB; Logsdon C; Jaffe RB; Coleman RL; Sood AK Clin Cancer Res; 2007 Jul; 13(14):4209-17. PubMed ID: 17634550 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332 [TBL] [Abstract][Full Text] [Related]
12. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358 [TBL] [Abstract][Full Text] [Related]
14. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645 [TBL] [Abstract][Full Text] [Related]
16. The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Okamoto K; Neureiter D; Alinger B; Meissnitzer M; Sass G; Schmitz V; Di Fazio P; Wissniowski T; Gahr S; Hohenstein B; Kaufmann B; Schlösser A; Haus U; Hahn EG; Herold C; Ocker M Int J Oncol; 2008 Oct; 33(4):733-42. PubMed ID: 18813786 [TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592 [TBL] [Abstract][Full Text] [Related]
19. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]